Multigene Testing for Hereditary Cancer: When, Why, and How

Restricted access

Multigene testing is a complicated area, with advantages and disadvantages of testing for hereditary cancer syndromes. Currently, NCCN does not endorse routing multiplex testing outside of a research setting, and/or intensive genetic counseling regarding risks and benefits. The 2017 NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian and Colorectal provide suggestions for mutation carriers identified by panel tests.

Correspondence: Kenneth Offit, MD, MPH, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. E-mail: offitk@mskcc.org
  • 1.

    DalyMBPilarskiRBerryM. NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2017. Accessed April 5 2017.

    • Search Google Scholar
    • Export Citation
  • 2.

    ProvenzaleDGuptaSAhnenDJ. NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Colorectal. Version 2.2016. Accessed April 5 2017.

    • Search Google Scholar
    • Export Citation
  • 3.

    PritchardCCMateoJWalshMF. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med2016;375:443453.

  • 4.

    DomchekSMBradburyAGarberJE. Multiplex genetic testing for cancer susceptibility. J Clin Oncol2013;31:12671270.

  • 5.

    BalmañaJDigiovanniLGaddamP. Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing. J Clin Oncol2016;34:40714078.

    • Search Google Scholar
    • Export Citation
  • 6.

    VogelVG. Reducing the risk of breast cancer with tamoxifen in women at increased risk. J Clin Oncol2001;16(18 Suppl):87S92S.

  • 7.

    TungNDomchekS MStadlerZ. Counseling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol2016;13:581588.

    • Search Google Scholar
    • Export Citation
  • 8.

    TrosmanJRWeldonCBDouglasMP. Payer coverage for hereditary cancer panels: barriers, opportunities, and implications for the Precision Medicine Initiative. J Natl Compr Canc Netw2017.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 151 151 16
PDF Downloads 59 59 4
EPUB Downloads 0 0 0